Results: Of 157 screened patients, 86 were eligible for study enrollment. The patients' age ranged from 65 to 98 years (mean, 78 6 8.2 years). The cohort of patients consisted of 61 men and 25 women. Of the 86 patients, 48% (n ¼ 41) of patients were discharged with an opioid prescription, and 11.4% (n ¼ 10) of patients continued to receive opioids for 1 year (271-365 days). Patients with opioid use for 1 year were found to have a significantly higher incidence of diabetes, three or more different opioid prescribers, and three or more opioid-dispensing pharmacies. In addition, patients with 1-year opioid use had a significantly higher mean rank for duration of use of nonopioid pain medications (neuroleptics and benzodiazepines) compared with patients with opioid use up to 270 days after discharge (c 2 ¼ 31.8; P < .0005, KruskalWallis test).
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Arteriovenous Fistula Remains the Best Hemodialysis Access Choice for Some Elderly Patients
Objective: The optimal choice of hemodialysis access in elderly patients remains controversial. This study was undertaken to determine hemodialysis-dependent life expectancy by age of the patient at dialysis initiation and to compare this with the durability of the various hemodialysis access options.
Methods: We abstracted data from our center's hemodialysis electronic database during a 10-year period to determine survival of patients on hemodialysis, stratified by decade of life at dialysis initiation. We also collected data on each dialysis access to determine primary and secondary patency of access types in the various age subgroups. Kaplan-Meier survival functions were generated to represent patients' survival and hemodialysis access patency.
Results: There were 794 patients who started hemodialysis for chronic renal replacement therapy at our center during the study period. Patients in the ninth decade of life (80-89 years) had a median survival of 1.5 6 0.5 years on dialysis, but this represented two divergent groups of patients. Patients aged 80 to 89 years who were selected for arteriovenous fistula (AVF) creation and used this access survived a median of 3.0 6 0.9 years, whereas those patients who had an AVF but did not use it had a median life expectancy of 1.5 years. Patients who dialyzed only through a central venous catheter (CVC) had a median life expectancy of 0.8 6 0.2 years (Table) . There were no age-related differences in AVF patency (median secondary patency, 5.3 6 0.4 years; Fig) . The secondary patency of AVFs was superior to that of both arteriovenous grafts (1.9 6 0.8 years) and CVCs (1.5 6 0.4 years).
Conclusions: Patients who use an AVF have an increased median life expectancy. These patients have a life expectancy that exceeds the secondary patency of arteriovenous grafts and CVCs. In this subset of patients, AVF remains the best hemodialysis option. Objective: Bioresorbable cardiovascular stents are currently developed to reduce the risk of long-term thrombosis and restenosis in diseased vessels. However, absorbable polymers remain mechanically weaker and Table. Median dialysis-dependent life expectancy for patients who used an alternative access vs arteriovenous fistula (AVF) for dialysis vs patients who had an AVF created but that was never used because of failure of maturation or the patient's preference for dialysis through a central venous catheter (CVC) The P value for alternative access compared with AVF is < .001 for all age groups combined. 
